Idera Pharmaceuticals, Inc. (IDRA) said it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA (MKGAY.PK). The milestone was achieved upon initiation of a Phase 2 trial by Merck KGaA of EMD 1201081, a novel agonist of Toll-like Receptor 9, or TLR9, in combination with cetuximab in second-line cetuximab-naive patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Under the terms of the agreement, the company is entitled to receive a payment of EUR 3.0 million from Merck KGaA.
The company expects to receive the milestone payment of EUR 3.0 million from Merck KGaA during the first quarter of 2010. The clinical trial is being conducted in eight countries, including the U.S.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.